The estimated HR for pancreatic cancer comparing 1 DDD of GLP-1RA vs 1 DDD of basal insulin, adjusted for length of diabetes, age, sex, socioeconomic status, ethnic origin, smoking, baseline BMI, and other GLM use, was 0.22 (95% CI, 0.11-0.41) for medication taken during the previous year. Here, INS is linked to pancreatic neoplasm.